Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (8327)	1/17/1999 2:24:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Back to the future! +george wohanka (2168 ) From: +Techperson XOMA gave a strong presentation at the Alex Brown Conference on Monday, including a one-hour breakout session. There was no news on the trauma study yet; that data should be on its way to six big pharma companies by the end of this week, but it is preliminary and won't be released yet. They have enrolled 65 of the 130 meningococcemia patients and have 6 deaths, so they are VERY suspicious that kids taking the placebo are dying and kids taking the drug are not. They clearly are wrestling with what to do, as in their minds it is approaching unethical to continue to give the placebo, yet they need to get enough data for an FDA signoff. The forthcoming climical trial oversight meeting will peek at the data and make a recommendation; sounded like June. The FDA asked them to try BPI against sepsis! Casey asked the FDA if they would change their standard to measure sepsis-caused deaths instead of all deaths. They said no, and he told them he could not spend the shareholders' money on a project sure to fail because the FDA has wrongheaded standards. IMHO, the value of their research pipeline is about to double or triple when the trauma data is released and the meningococcemia study is converted to open label because the drug is so effective. IMHO, the value of their research pipeline is about to double or triple when the trauma data is released and the meningococcemia study is converted to open label because the drug is so effective. Note I believe Techperson was Murphy. Pay particular attention to this: The FDA asked them to try BPI against sepsis! Casey asked the FDA if they would change their standard to measure sepsis-caused deaths instead of all deaths. They said no, and he told them he could not spend the shareholders' money on a project sure to fail because the FDA has wrongheaded standards. XXXXXXXX My question is was something else said? One can understand the FDA not wanting to split hairs in trying to determine who died from actual sepsis and who died from from say the original cause of the sepsis, a gunshhot etc. So I wonder what the real disagreement was about.